BackX4 Pharmaceuticals Overview
X4 Pharmaceuticals Inc

X4 Pharmaceuticals Target Price

Analysts' average 12-month price target for X4 Pharmaceuticals is $11.

Get informed when a big investor buys or sells

+ Follow

Share Price

$2.83

Average Target Price

$11.00288.7% upside

1 analysts in the last 4 months

High: $11 | Low: $11

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-10Wells Fargo$11288.7% upsideOpen
2026-06-02Leerink PartnersThomas Smith$12324% upsideOpen
2026-03-09Guggenheim$12324% upsideOpen
2025-12-05Stifel NicolausJames Condulis$10253.4% upsideOpen
2025-11-05Stifel NicolausStephen Willey$7.5165% upsideOpen
2025-08-29Stifel NicolausStephen Willey$9218% upsideOpen
2025-08-13H.C. WainwrightSwayampakula Ramakanth$3.523.7% upsideOpen
2022-12-22Cantor Fitzgerald$36% upsideOpen
2022-12-11Piper SandlerEdward Tenthoff$36% upsideOpen
2022-11-30H.C. Wainwright$576.7% upsideOpen

X4 Pharmaceuticals (XFOR) FAQ

X4 Pharmaceuticals posts a target price of $11. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $11 for XFOR means covering analysts, on average, see the stock 288.7% upside of $2.83 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for XFOR's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; X4 Pharmaceuticals's other metric pages and overview cover the third.

Judging X4 Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $11 here, then scan peer and history charts to see if the gap is persistent.